Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical Gefitinib in Breast Cancer
NCT00637026Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Molecular alterations occuring in breast cancer tissue following Iressa treatment. Started Jul 2003; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00637026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00637026.